Ovarian Malignancy Risk (ROMA) ROMA

Synonyms
Allscripts (AEHR) Order Name	ROMA
Sunrise Clinical Manager (SCM) Order Name	Ovarian Malignancy Risk (ROMA)
Clinical Info	The ROMA™ (Risk of Ovarian Malignancy Algorithm) calculation combines the results of the Roche Elecsys HE4 assay, Elecsys CA 125 II assay and menopausal status into a numerical score (Roche). The ROMA value is intended to aid in assessing whether a premenopausal or postmenopausal woman who presents with an ovarian adnexal mass is at high or low likelihood of finding malignancy on surgery.
Specimen Type	Blood
Container	Gold Top Tube
Collection Instructions	Container/Tube: Gold Top or Red top tube Specimen: 1.75 ml Serum (1.0 mL min-this volume does not allow for repeat testing) Transport Temperature: Refrigerated -Stable for 14 Days Note: This test may exhibit interference when sample is collected from a person who is consuming a supplement with a high dose of biotin (also termed as vitamin B7 or B8, vitamin H, or coenzyme R). It is recommended to ask all patients who may be indicated for this test about biotin supplementation. Patients should be cautioned to stop biotin consumption at least 72 hours prior to the collection of a sample.
Transport Instructions	Refrigerated -Stable for 14 Days
Specimen Stability	5 Days Room Temperature 14 Days Refrigerated
Methodology	Electrochemiluminescence immunoassay (ECLIA)
Days Performed
Performing Laboratory	LabCorp of America
CPT	81500
PDM	5904898
Result Interpretation Use of ROMA for stratification into low and high likelihood groups for finding malignancy on surgery Using preoperatively collected serum samples, ROMA value were determined and the patients were stratified into a low or high likelihood group for finding malignancy on surgery.⁹ Samples were tested at three US testing sites. The following cut-off points were used in order to provide a specificity level of 75%: Premenopausal women: • ROMA score ≥1.14: high likelihood of finding malignancy • ROMA score <1.14: low likelihood of finding malignancy Postmenopausal women: • ROMA score ≥2.99: high likelihood of finding malignancy • ROMA score <2.99: low likelihood of finding malignancy The reported results include both the likelihoods and associated ROMA scores for premenopausal and postmenopausal women on a scale of 0-10.
Forms